Zinc8 Energy Solutions

LEXARIA BIOSCIENCE (NASDAQ: LEXX) STOCK QUOTE

Last Trade: US$3.31 0.07 2.28
Volume: 7,075
5-Day Change: 18.91%
YTD Change: -17.86%
Market Cap: US$19.700M

LATEST NEWS FROM LEXARIA BIOSCIENCE

August 11, 2022
Lexaria Bioscience Discusses Valuation Metrics for Biotech Industry
Third Party Analysis for Biotech and Pharma Industries Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following information to its stakeholders as an aid to conveniently researching and understanding various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. " Biotech... Read More
August 11, 2022
Lexaria Bioscience Focused on Filling Need for Hypertension Treatment Solution
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/9kD5b In its 2021 industry report, ReportLinker estimated the global anti-hypertensive drugs market at $24.17 billion in 2020 on its way to reach $27.81 billion... Read More
August 10, 2022
Lexaria Bioscience Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
Significant Milestone Achieved in Commercial Product Development Program Abbreviated 505(b)(2) Strategy Confirmed as an Appropriate NDA Pathway Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that it has received a positive full written response from the Food and Drug Administration ("FDA") from its pre-Investigational New... Read More
August 9, 2022
Lexaria Bioscience Developing Powerful Tech to Treat Hypertension
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114 million adults... Read More
July 27, 2022
Lexaria Bioscience DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing with Lexaria's DehydraTECH™-processed cannabidiol ("DehydraTECH-CBD") has been completed in its multi-week human clinical hypertension study HYPER-H21-4, and that no serious adverse events have been reported as a result of the dosing. HYPER-H21-4, is a randomized,... Read More
June 8, 2022
Lexaria Bioscience Grants License to AnodGen Bioceuticals
DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand markets Lexaria to receive royalty revenue from DehydraTECH product sales Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the awarding of a five-year, non-exclusive DehydraTECH license (the "License") from its wholly-owned subsidiary,... Read More
June 6, 2022
Lexaria Bioscience Files Pre-IND Meeting Request Letter with U.S. FDA
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has successfully filed a pre-Investigational New Drug ("IND") meeting request letter with the U.S. Food and Drug Administration ("FDA"). The FDA has already responded to and confirmed Lexaria's filing. A target date of July 30, 2022, has been provided to Lexaria, subject... Read More
June 3, 2022
Lexaria Bioscience Grants Exclusive License to Premier Wellness Science Co for Strategic and Long-Term Partnership in the Japanese Market
Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivity Lexaria to receive royalty revenue from DehydraTECH product sales Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce a significant exclusive* commercial licensing agreement (the "Agreement") in Japan with Premier Wellness Science... Read More
June 2, 2022
Lexaria Bioscience Grants License to Valcon Medical for the European Market
Contract Manufacturing Organization first in Europe to License DehydraTECH Lexaria will receive milestone fees and royalty payments from product sales Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the awarding of a European and United Kingdom ("UK") DehydraTECH license for medical cannabis applications from Lexaria... Read More
June 1, 2022
Lexaria Bioscience Announces 2022 Annual Meeting Results
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting (the "Meeting"). On May 31, 2022 at 1:00 p.m. (Pacific Time), the Company held the Meeting whereby there were 2,927,321 shares of the Company represented in person or by proxy at the meeting, constituting 49.2% of the Company's issued share capital... Read More
May 26, 2022
Lexaria Bioscience Stands as Global Leader in Delivery Tech Space
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/WNblw The fact remains that an estimated 1.1 billion people smoked cigarettes in 2019. According to stats from the World Health Organization, a stunning 780 million... Read More
May 25, 2022
Lexaria Bioscience Offers Breakthrough Delivery Tech in Hot Nicotine Space
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Nicotine Surges as Smoking Sags,” please visit: https://nnw.fm/WNblw Seems like yesterday people were smoking cigarettes... Read More
April 21, 2022
Lexaria Bioscience Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
25 th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States Patent and... Read More
April 19, 2022
Lexaria Bioscience Commences Multi-Week Human Clinical Hypertension Study
HYPER-H21-4 will evaluate DehydraTECH TM -CBD for reducing blood pressure together with other potential clinical benefits This study is designed to enhance Lexaria's probabilities of success with its expected subsequent Investigational New Drug application filing Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it... Read More
April 14, 2022
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug Administration Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that all data analyses from its simulated pulmonary hypertension... Read More
April 12, 2022
Lexaria Bioscience Provides Update on Human Nicotine Study NIC-H22-1
Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. Study NIC-H22-1 is a minimum 36-person human... Read More
April 11, 2022
Lexaria Bioscience Begins New Nicotine Formulation Creation and Evaluation Program
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered new agreements with Altria Client Services, LLC ("Altria"). Under the terms of these agreements, Lexaria will receive a fee to provide certain DehydraTECH powder-based nicotine formulations to be evaluated by Altria. The new agreements are in effect until March 31, 2023.... Read More
March 15, 2022
Lexaria Bioscience Begins DehydraTECH-CBD Epilepsy Research Program
Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECH TM -CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to commence dosing. Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that the first phase of its epilepsy research program... Read More
March 8, 2022
Lexaria Bioscience Granted Important New Oral Nicotine Patent
Newest granted patent expands worldwide patent portfolio to 24 Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted a new patent entitled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof". The new Australian patent expands upon Lexaria's international intellectual property rights to apply... Read More
January 18, 2022
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2 " Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, comments on an independent January 10 study, available here , that discovered that "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants". In an interview granted to vice.com, lead research... Read More
December 29, 2021
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
Dosing is expected to begin by April, 2022 Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the " Company " or " Lexaria "), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("IRB") approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4. This study should "de-risk" outcomes prior to Lexaria's planned entry into... Read More
December 16, 2021
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the " Company " or " Lexaria "), a global innovator in drug delivery platforms announces that it has entered into an advertising and media agreement (the " Contract ") for media buys and digital marketing with SRAX, Inc. (" SRAX "). "Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long media outreach... Read More
December 14, 2021
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week. Formal hospital and ethics board approvals for human clinical study HYPER-H21-3 had been received in March. Study HYPER-H21-3 used a placebo-controlled and blinded design, with... Read More
December 8, 2021
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
Results suggest broader applications for DehydraTECH-CBD beyond hypertension Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECH TM -processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its application to treatment of... Read More
December 6, 2021
Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference
Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space. Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/ . About the Benzinga Global Small Cap Conference... Read More
November 10, 2021
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for several new and ongoing DehydraTECH TM applied R&D programs for 2022. The studies mentioned herein are only a fraction of Lexaria's 2022 work programs. "Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart... Read More
November 3, 2021
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
DehydraTECH-CBD also being evaluated in three other human clinical studies Positive studies would support Lexaria's regulatory approval plans Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces a significant new study to expand its hypertension clinical program and provides updates on three ongoing human clinical studies evaluating its... Read More
November 1, 2021
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECH TM -CBD for reducing seizure activity Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has commenced an important new study exploring whether DehydraTECH TM -CBD evidences superior ability to inhibit seizure activity compared to both generic cannabidiol... Read More
October 20, 2021
Lexaria THC Test Results Come in as MORE Act Gains Momentum in Congress
Lexaria Bioscience Corp , developers of the revolutionary DehydraTECH™ drug delivery technology, is in the news again this week. On October 13 th , the British Columbia-based pharmaceutical company released study results on THC-A21-1, a THC oral format. The study revealed that Lexaria's DehydraTECH™ THC delivers THC levels to blood-plasma at a rate that is roughly three times faster than standard MCT-based THC. Oral... Read More
October 13, 2021
Lexaria's Technology Proven to Deliver Oral THC More Effectively
DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its recent oral tetrahydrocannabinol ("THC") absorption study THC-A21-1 revealed that DehydraTECH TM -THC delivered via oral ingestion required only 15 minutes to deliver... Read More
October 5, 2021
DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete
Lexaria Bioscience Corp (NASDAQ: LEXX) is making headlines again this week. In a study conducted by a leading independent testing facility, DehydraTECH™ 2.0 nicotine pouches easily outperformed generic nicotine benzoate pouches, hitting peak delivery rates within eight minutes, and then again at thirty minutes. The generic pouches hit peak at forty-five minutes. It's a significant disparity when comparing two similar... Read More
October 5, 2021
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls Peak levels achieved were up to 10x higher than controls Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECH TM -nicotine delivered via the oral pouch... Read More
September 9, 2021
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that Chairman & CEO Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021. Mr. Bunka will provide an overview of the Company's latest news and updates which will become available beginning... Read More
September 8, 2021
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
Positive results using DehydraTECH-CBD support progressing to FDA IND application Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms today announced it is formally beginning the process towards an Investigational New Drug ("IND") application filing with the Food and Drug Administration ("FDA") with its DehydraTECH-processed cannabidiol... Read More
September 7, 2021
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is extremely pleased to issue initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH TM -processed cannabidiol ("CBD") for potential... Read More
August 17, 2021
Winning Formulation; Lexaria Takes Strategic Aim at High Value Hypertension and Antiviral Therapeutics Markets with Robust Drug Delivery Technology
Lexaria Bioscience Corp. (NASDAQ: LEXX) has been working on making pills easier to swallow since 2006, and its absorption into shareholder portfolios has been speeding up of late, just like their technology. DehydraTECH: a cure for other cures Lexaria's tentpole technology is DehydraTECH, a simple, cost-effective tandem of formulation and production steps which masks unpleasant taste and odor, avoids much of the impact on... Read More
July 29, 2021
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is extremely pleased to issue partial results from human clinical study HYPER-H21-1 evaluating DehydraTECH TM -processed cannabidiol ("CBD") for potential... Read More
July 28, 2021
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its DehydraTECH TM technology has been embraced by consumer brands now available for sale in over 7,000 stores across the US. "Lexaria's technology is enabling... Read More
July 27, 2021
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
Additionally, second patent award received in Japan Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed in its second human clinical study of 2021. Human clinical study HYPER-H21-2 consisted of 16 human volunteers who were pre- or mildly hypertensive and received three separate doses of 150 mg... Read More
July 26, 2021
Lexaria Receives US$3,817,643 From Warrant Exercises
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the receipt of US$3,817,643 from the exercise of share purchase warrants (the "Warrants"). The Warrants were issued by the Company pursuant to its January 2021 public underwritten offering (the "Offering") whereby the shares and Warrants issued thereunder were registered... Read More
July 22, 2021
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
All objectives evaluating DehydraTECH ™ drug delivery platform successfully achieved Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps. Lexaria's objectives in its 2021 antiviral drug examination program thus far have been to determine... Read More
July 21, 2021
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. This study demonstrated that DehydraTECH TM enabled colchicine, the latest of several drugs... Read More
July 15, 2021
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs Lexaria Bioscience Corp. ( NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada's premier federally funded research organization, the National Research Council ("NRC").... Read More
July 13, 2021
Lexaria Receives Patent Protection in Japan
New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces an additional expansion of its intellectual property portfolio with its first-ever patent granted in Japan. The patent is titled "Stable ready-to-drink beverage compositions comprising... Read More
July 5, 2021
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily delist its common shares from the Canadian Securities Exchange (the “CSE”). It is expected that the close of business on Wednesday, July 7, 2021 will be the final trading day for Lexaria on the CSE. At the open of the... Read More
June 29, 2021
Lexaria Announces 2021 Annual Meeting Results
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting'). On June 28, 2021 at 1:00 p.m. (Pacific Time), the Company held the Meeting whereby there were 2,735,413 shares of the Company represented in person or by proxy at the meeting, constituting 53.6% of the Company's issued... Read More
June 21, 2021
Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45... Read More
June 17, 2021
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a major milestone this week with their patented DehydraTECH TM technology. An IC50 in vitro study was completed with COVID-19 SARS-CoV-2 antivirals Remdesivir and Ebastine and concluded that their formulation and processing methodology "did not negate the known efficacy of those compounds." "This test is conducted as a pass/fail," said Chris Bunka, CEO of Lexaria Bioscience. "We... Read More
June 15, 2021
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce positive results from its tolerability and pharmacokinetic ("PK") animal study VIRAL-A20-2, evaluating DehydraTECH-enabled remdesivir and ebastine.... Read More
June 9, 2021
Lexaria Provides Progress Report on Six R&D Programs
All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strategic partnerships Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this... Read More
June 7, 2021
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria's Patented Technology for Hypertension Relief Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation Second Human Clinical Study, Hyper-H21-2, To Commence Immediately Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that... Read More
June 3, 2021
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3. "The main purpose of the study was to confirm that Lexaria's DehydraTECH... Read More
May 20, 2021
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
New formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH ™ 2.0" cannabidiol ("CBD") formulations in its second 2021 applied research and... Read More
May 12, 2021
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces further expansion of its intellectual property portfolio with its first-ever patent granted in India. The patent is titled "Stable ready-to-drink... Read More
March 16, 2021
Lexaria's Antiviral Drug Evaluation Program Progressing
Two of the four planned studies progressing to examine DehydraTECH™ with antivirals targeting SARS-CoV-2 / COVID-19 Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (C NSX :LXX. CN ) (OTC:LXRP) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) program. “It’s been a... Read More
March 15, 2021
Rapid Progress in Hypertension Studies by Lexaria
Five studies underway to examine DehydraTECH TM CBD for Hypertension Kelowna, British Columbia - TheNewswire - March 15, 2021 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (C NSX :LXX. CN ) (OTC:LXRP) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces extensive progress in five studies focused on the performance of DehydraTECH TM CBD as a treatment for hypertension. Three human... Read More
March 11, 2021
Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka is presenting and will be available to meet with investors and analysts... Read More
February 16, 2021
Lexaria Enters Investor Relations Agreement
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces its engagement of Accretive Capital LLC, a Delaware limited liability company doing business as Benzinga, to provide investor relations services (“ IR Services”) to the Company. The Company has agreed to pay Benzinga US$16,000 for the provision of its IR Services... Read More
February 11, 2021
Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies
Hypertension program evaluating effectiveness of DehydraTECH-processed CBD now consists of three human clinical studies and two animal studies Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces significant progress in its 2021 applied research and development (R&D) program with additional focus on hypertension.... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS